ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $9.55M (cash outflow) rose 58.5% year over year, ahead of the +39.8% change in trailing-twelve-month net income. Sequentially, it rose 22.7% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.
Context
- Net income amounted to 69.1% of revenue in FY2025, up 8.8 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$32.99M (+29.2%) for the fiscal year ending Dec 2026, a slowdown from the +35.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.55M+22.7% QoQ
- Last fiscal yearDec 2025
- -$25.54M+35.0% YoY
- LTMMar 2026
- -$29.07M+39.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +58.5% | +52.2% | -6.3 pp |
| 1 year | +35.0% | +29.2% | -5.9 pp |
| 3-year CAGR | +15.8% | -1.6% | -17.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (25.54M) USD
- Year-over-year change
- -35.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.54M) | -35.0% |
| FY2024 | 2024-12-31 | (18.91M) | +14.4% |
| FY2023 | 2023-12-31 | (22.09M) | -34.4% |
| FY2022 | 2022-12-31 | (16.43M) | -14.1% |
| FY2021 | 2021-12-31 | (14.41M) | — |
Net Income vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +39.8% is the 4th highest of 10, against a peer median of +24.5%.
- Net income amounts to 71.6% of revenue for CLPT, versus a peer median of 10.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $178.8M USD | +29.8% | +46.5% | — | |
| LTM Mar 2026 | $178.05M USD | +24.5% | +67.1% | 21.6% | |
| LTM Apr 2026 | $82.7M USD | +98.8% | — | 9.6% | |
| LTM Mar 2026 | $78.21M USD | +158.9% | -26.7% | 90.7% | |
| LTM Mar 2026 | $74.4M USD | -80.7% | — | 10.4% | |
| LTM Mar 2026 | $74M USD | +557.6% | — | 36.2% | |
| LTM Mar 2026 | $29.07M USD | +39.8% | +15.8% | 71.6% | |
| LTM Mar 2026 | $20.51M USD | -54.7% | -61.3% | 8.8% | |
| LTM Mar 2026 | $16.7M USD | -37.1% | -32.4% | 8.1% | |
| LTM Mar 2026 | CA$10.98M CAD | -89.7% | -65.1% | 1.2% | |
| Peer median (excluding CLPT) | — | +24.5% | -29.6% | 10.0% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.41M) | (16.43M) | (22.09M) | (18.91M) | (25.54M) |
| Depreciation & Amortization | 692K | 777K | 1.51M | 1.9M | 982K |
| Deferred Income Tax | 202K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.08M | 4.13M | 6.08M | 6.91M | 8.18M |
| Change in Working Capital | (1.68M) | (4.29M) | (1.4M) | 1.4M | (9.81M) |
| Accounts Receivables | 627K | (211K) | (1.8M) | (1.21M) | (268K) |
| Inventory | (1.71M) | (4.42M) | 1.25M | 743K | (103K) |
| Accounts Payables | (762K) | 1.59M | 0 | 3.11M | (7.52M) |
| Other Working Capital | 165K | (1.25M) | (846K) | (1.24M) | (1.92M) |
| Other Non-Cash Items | 425K | 3.78M | 2.18M | (245K) | 2.27M |
| Operating Cash Flow | (12.7M) | (16.17M) | (13.72M) | (8.95M) | (23.93M) |
| Capital Expenditures | (168K) | (253K) | (717K) | (275K) | (522K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1.14M |
| Purchases of Investments | 0 | (21.59M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 12M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 9.67M | 0 | 0 |
| Investing Cash Flow | (168K) | (10.74M) | 8.95M | (275K) | 615K |
| Debt Repayment | 0 | 0 | 0 | (10M) | 48.09M |
| Common Stock Issued | 46.79M | 745K | 0 | 16.15M | 3.95M |
| Common Stock Repurchased | 0 | 0 | (210K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 90K | (336K) | 506K | 40K | (1.86M) |
| Financing Cash Flow | 46.88M | 409K | 296K | 6.19M | 50.18M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 34.01M | (26.49M) | (4.48M) | (3.04M) | 26.87M |
| Free Cash Flow | (12.87M) | (16.42M) | (14.44M) | (9.23M) | (24.45M) |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.